Vaxxinity logo

Vaxxinity(OTC) VAXX

Market Cap$14.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 YearN/A
1 Year-99%
1 Month+0%
$0.00
+0.00%
+0.00Today
Vaxxinity last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-25
Vaxxinity stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-09-18
1 month+0%USD 0.002026-08-26
3 month-99.29%USD 0.012026-06-26
Year to date-66.67%USD 0.002025-12-31
1 year-99%USD 0.012025-09-25
3 year-99.99%USD 1.352023-09-26
Since inception-100%USD 16.552021-11-11

Vaxxinity Financials at a Glance

Market Cap

$14.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$56.94M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.00

Volume

2,373

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.20

Estimated Earnings Date

Aug 31, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vaxxinity

Vaxxinity, Inc. is a biotechnology company focused on developing innovative therapeutic candidates for neurological disorders and infectious diseases. Founded in 2014 and headquartered in Dallas, Texas, the company aims to address significant health challenges, particularly those related to coronaviruses and neurodegenerative conditions.

Products and Services
  • UB-311: Phase 2 candidate targeting Alzheimer's disease
  • UB-312: Investigational therapy for Parkinson's disease and related disorders
  • UB-612: Phase 3 candidate engineered to neutralize SARS-CoV-2
Growth Outlook
  • Strong pipeline with multiple candidates in various clinical trial phases
  • Focus on high-demand therapeutic areas, including Alzheimer's and COVID-19
  • Potential for strategic partnerships to enhance development and commercialization
Financial Highlights
  • Recent quarterly net income of -$11.39 million, reflecting ongoing R&D investments
  • Cash and short-term investments totaled $30.4 million as of Q4 2023
  • Current ratio of 1.89 indicates strong liquidity position
Vaxxinity, Inc. is positioned in a rapidly evolving biotechnology sector, with a focus on addressing critical health issues. The company's diverse pipeline includes candidates targeting both neurological disorders and infectious diseases, which are areas of significant unmet medical need. The ongoing clinical trials and research efforts reflect a commitment to innovation and potential market impact. Financially, Vaxxinity has maintained a solid liquidity position, with substantial cash reserves to support its research and development activities. The recent net income figures indicate a strategic investment in future growth, as the company continues to advance its clinical programs. The current ratio suggests that Vaxxinity is well-equipped to meet its short-term obligations, providing a level of financial stability as it navigates the complexities of the biotechnology landscape. Overall, Vaxxinity, Inc. presents an intriguing opportunity for investors interested in the biotechnology sector, particularly those focused on innovative therapies for pressing health challenges.
AI Generated • Sep 8, 2026

Industry

Biotechnology

Employees

57

CEO

Mei Mei Hu

Headquarters

Merritt Island, FL 32953, US

VAXX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-0.15%

Return on Capital

-203.96%

Return on Assets

-0.13%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$14.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

140.66M

Volume

2.37K

Avg. Volume

6.44K

Financials (TTM)

Gross Profit

-$2.23M

Operating Income

-$58.33M

EBITDA

-$54.01M

Operating Cash Flow

-$57.24M

Capital Expenditure

-$803.00K

Free Cash Flow

-$58.04M

Cash & ST Invst.

$30.40M

Total Debt

$15.17M

Vaxxinity Performance Analysis

Vaxxinity annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 66,000N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
Vaxxinity sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-31N/A
Q22023-06-30N/A
Q32023-09-30N/A
Q42023-12-31N/A
Vaxxinity annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.09N/A
20222022-12-31USD -0.60-45.4%
20232023-12-31USD -0.45-24.7%
Vaxxinity sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-316.3%
Q22023-06-3026.7%
Q32023-09-309.1%
Q42023-12-3110.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$456.00K

+15.6%

Gross Margin

0.00%

N/A

Market Cap

$14.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$247.37

N/A

Employees

57

N/A

Net Income

-$11.39M

+44.4%

EBITDA

-$10.75M

+45.3%

Quarterly Fundamentals

Name
Q4 2023YOY CHG

Total Cash

$30.40M

-65.0%

Total Debt

$15.17M

+4.3%

Accounts Receivable

$414.00K

+0.0%

Inventory

$0.00

-100.0%

Long Term Debt

$13.26M

+1.7%

Short Term Debt

$1.91M

+26.7%

Return on Assets

-0.13%

N/A

Return on Invested Capital

-2.18%

N/A

Free Cash Flow

-$12.26M

+17.0%

Operating Cash Flow

-$11.85M

+18.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QBIOQ BioMed Inc.
$0.00-0.00%
SDCCQSmileDirectClub Inc Class A
$0.00+0.00%
XSNXNovAccess Global Inc.
$0.00+0.00%
HLUNHEALTHeUNIVERSE, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.54+3.55%
INTCIntel
$123.00-3.45%
NVDANvidia
$225.07+0.22%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.94-3.02%

Questions About VAXX

What is the current price of Vaxxinity?

Vaxxinity is trading at $0.00 per share.

What is the 52-week range for Vaxxinity?

Over the past 52 weeks, Vaxxinity has traded between $0.00 and $0.20.

How much debt does Vaxxinity have?

As of the most recent reporting period, Vaxxinity reported total debt of $15.17M.

How much cash does Vaxxinity have on hand?

Vaxxinity reported $5.04M in cash and cash equivalents in its most recent financial results.

What is Vaxxinity’s dividend yield?

Vaxxinity does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.